Back to resultsA Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma
Primary Purpose
Metastatic Soft-tissue Sarcoma
Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
NOX66
NOX66
NOX66
NOX66
Doxorubicin
Sponsored by
About this trial
This is an interventional treatment trial for Metastatic Soft-tissue Sarcoma focused on measuring Doxorubicin, Dose-escalation study, Dose-expansion study, Maximum tolerated dose
Eligibility Criteria
Inclusion Criteria:
- Adult patients with a histologically confirmed diagnosis of metastatic or recurrent soft tissue sarcoma
- Patients for whom treatment with doxorubicin is considered to be appropriate
- Left ventricular ejection fraction ≥ 50%
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Disease that is considered measurable according to RECIST v1.1.
Exclusion Criteria:
- Histologically or cytologically confirmed Kaposi's sarcoma, gastrointestinal stromal tumor (GIST), extra-skeletal myxoid chondrosarcoma, epithelioid hemangioendothelioma, and desmoid tumor
- Untreated metastases to the central nervous system
- Received previous treatment with anthracyclines and anthracenediones
- Previous radiation therapy to the mediastinal or pericardial area
- A known allergy to any of the treatment components
- Patient not willing to use suppositories
- Patients with a colostomy
- Patients who have had a colectomy (total or left hemicolectomy) with re-anastomosis
- Patients for whom administration of the suppositories are likely to cause pain (e.g., inflamed hemorrhoids, fissures, or lesions of the anus or rectum)
- Patients with fecal impaction, chronic idiopathic constipation, or chronic diarrhea or alternating irritable bowel disease
- Patients with inflammatory bowel disease
- Previous treatment with an investigational agent or the non-approved use of a drug or device within 4 weeks before study entry
- Uncontrolled diabetes mellitus
- Patients who require concomitant use of strong inhibitors or inducers of CYP3A4, CYP2D6 or P- glycoprotein (P- gp)
Sites / Locations
- City of Hope
- Mayo Clinic Florida - Oncology
- Mayo Clinic
- Site name Washington University School of Medicine in Saint Louis
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Experimental
Arm Label
Dose-Escalation Cohort 1: NOX66 800 mg + Doxorubicin
Dose-Escalation Cohort 2: NOX66 1200 mg + Doxorubicin
Dose-Escalation Cohort 3: NOX66 1800 mg + Doxorubicin
Dose-Expansion Cohort: NOX66 + Doxorubicin
Arm Description
Outcomes
Primary Outcome Measures
Dose Escalation: Number of patients with dose-limiting toxicities (DLTs)
Determination of the MTD of NOX66 in combination with doxorubicin. MTD is defined as the dose level at which no more than 1 patient out of 6 experiences a DLT at the end of Cycle 1.
Number of patients with adverse events (AEs) for NOX66
Characterization of the safety and tolerability of NOX66.
Number of patients with change in brain natriuretic peptide (BNP) levels from baseline
The number of patients with BNP levels greater than 500 pg/mL and with BNP levels between 100 and 500 pg/mL from baseline will be presented.
Number of patients with change in troponin levels from baseline
Number of patients with change in troponin levels from baseline will be evaluated to characterize safety and tolerability of NOX66.
Secondary Outcome Measures
Dose-Escalation (Monotherapy): Maximum observed blood drug concentration (Cmax) for idronoxil and idronoxil metabolites
Determination of single-and multiple-dose pharmacokinetics (PK) of idronoxil
Dose-Escalation (Monotherapy): Time to reach Cmax (Tmax) for idronoxil and idronoxil metabolites
Determination of single-and multiple-dose PK of idronoxil
Dose-Escalation (Monotherapy): Area under the blood concentration time curve (AUC) from time 0 to the last measurable concentration (AUC-last) for idronoxil and idronoxil metabolites
Determination of single-and multiple-dose PK of idronoxil
Dose-Escalation (Monotherapy): AUC from time 0 to end or dosing interval (τ) [AUCτ] for idronoxil and idronoxil metabolites
Determination of single-and multiple-dose PK of idronoxil
Dose-Escalation (Monotherapy): AUC from time 0 to infinity (AUCinf) for idronoxil and idronoxil metabolites
Determination of single-and multiple-dose PK of idronoxil
Dose-Escalation (Monotherapy): Terminal elimination rate constant (kel) for idronoxil and idronoxil metabolites
Determination of single-and multiple-dose PK of idronoxil. Terminal elimination rate constant will be calculated from a semi-log plot of the blood concentration versus time (kel^a)
Dose-Escalation (Monotherapy): Terminal elimination phase half-life (T1/2)
Determination of single-and multiple-dose PK of idronoxil
Dose-Escalation (Combination) and Dose-Expansion: Plasma concentrations of idronoxil and idronoxil metabolites or doxorubicin and doxorubicinol
Determination of single-and multiple-dose PK of idronoxil and doxorubicin
Dose-Escalation and Dose-Expansion: Disease control rate (DCR)
Evaluation of preliminary efficacy of NOX66 in combination with doxorubicin. DCR is defined as the percentage of patients with a best overall response of complete response (CR), partial response (PR) or stable disease, and will be assessed based on change from baseline imaging by (Response Evaluation Criteria in Solid Tumors [RECIST] v1.1.
Dose-Escalation and Dose-Expansion: Objective response rate (ORR)
Evaluation of preliminary efficacy of NOX66 in combination with doxorubicin. The ORR, defined as the percentage of patients with CR and PR, and will be assessed based on change from baseline imaging by (RECIST) v1.1.
Dose-Escalation and Dose-Expansion: Complete response (CR)
Evaluation of preliminary efficacy of NOX66 in combination with doxorubicin. CR will be assessed based on change from baseline imaging (RECIST) v1.1.
Dose-Escalation and Dose-Expansion: Partial response (PR)
Evaluation of preliminary efficacy of NOX66 in combination with doxorubicin. PR will be assessed based on change from baseline imaging (RECIST) v1.1.
Dose-Escalation and Dose-Expansion: Stable disease (SD)
Evaluation of preliminary efficacy of NOX66 in combination with doxorubicin. SD will be assessed based on change from baseline imaging (RECIST) v1.1.
Dose-Escalation and Dose-Expansion: Progression free survival (PFS)
Evaluation of preliminary efficacy of NOX66 in combination with doxorubicin. PFS is defined as the time in months from initial treatment until death, disease progression, or censoring.
Dose-Escalation and Dose-Expansion: Progressive disease (PD)
Evaluation of preliminary efficacy of NOX66 in combination with doxorubicin. PD will be assessed based on change from baseline imaging (RECIST) v1.1.
Dose-Escalation and Dose-Expansion: Overall survival (OS)
Evaluation of preliminary efficacy of NOX66 in combination with doxorubicin. OS is defined as the time in months from initial treatment until death or censoring.
Dose-Escalation and Dose-Expansion: Change from baseline in European Organization for Research and Treatment Core Quality of Life Questionnaire v3.0) (EORTC QLQ-C30)
Determination of quality of life (QOL) of NOX66 in combination with doxorubicin. The questionnaire assesses important functioning domains (e.g., physical, emotional, social) and common cancer symptoms (e.g., fatigue, pain, nausea, vomiting, appetite loss). The instrument is composed of 30 items. All symptom scales range from 1-4 with higher values representing higher levels of symptoms, except for the items that evaluate the overall quality of life which are rated on a 7-point scale (range 1-7) where higher scores represent a better quality of life.
Fatigue change from baseline measured using the EORTC QLQ-FA12 questionnaire
Determination of quality of life (QOL) of NOX66 in combination with doxorubicin. Fatigue will be measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - EORTC QLQ-FA12. The QLQ-FA12 incorporates three multi-item scales to assess physical fatigue, emotional fatigue, and cognitive fatigue. In addition, two single items assess interference with daily life and social sequelae. All of the scales and single-item measures range in score from 0 to 100. For all the scales and single items, a high score represents a high level of symptomatology or problems.
Change from baseline in brief pain inventory- Short Form (BPI-SF) questionnaire
Determination of quality of life (QOL) of NOX66 in combination with doxorubicin. The effects of NOX66 on pain and other cancer-related signs and symptoms will be explored. Worst pain, general pain and pain's interference with daily life will be assessed during the study drug using the BPI-SF. The BPI-SF comprises a total of 15 items measuring 2 domains: pain severity and pain interference. Items measuring pain severity (including 'worst pain') are rated on an 11 point numeric rating scale ranging from 0=No pain to 10=Pain as bad as you can imagine. Higher scores mean a worse outcome.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05100628
Brief Title
A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma
Official Title
A Dose Escalation and Dose Expansion Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma - CEP-2
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Terminated
Why Stopped
Slow recruitment
Study Start Date
February 11, 2022 (Actual)
Primary Completion Date
May 1, 2023 (Actual)
Study Completion Date
May 26, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Noxopharm Limited
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a Phase I, open-label, dose-escalation and dose-expansion study of NOX66 given rectally, in cohorts of patients with metastatic soft tissue sarcoma (STS) who have not been exposed to anthracycline therapy, using a fixed dose-escalation schema every 21 days to establish the maximum tolerated dose (MTD) of the combination of NOX66 and doxorubicin.
Detailed Description
The study will contain dose-escalation cohorts and dose-expansion cohorts. The study design allows an exploration of different doses of NOX66 with safety monitoring to ensure the safety of the patients.
Dose-escalation cohorts: It will include three planned Treatment Groups (800, 1200, 1800 mg daily) and patients enrolled in these groups will receive 7 days of monotherapy treatment with NOX66 followed by a 5-day washout period. Thereafter, patients will enter a combination therapy (only if no significant toxicity is observed during monotherapy). This will commence with Cycle 1, which will consist of 7 days of NOX66, and on Day 2 of the 21-day cycle, doxorubicin will be administered. Patients will continue to be treated for up to 6 x 21-day cycles of NOX66 and doxorubicin. New patients will be entered at the next dose level of NOX66, if no dose-limiting toxicities have occurred among the first 3 patients at the end of cycle 1. During the dose-escalation, MTD of the combination of NOX66 and doxorubicin will be determined.
Dose-expansion cohort: On completion of the dose-escalation cohort, patients will be enrolled into a dose-expansion at the MTD of the combination of NOX66 and doxorubicin. All patients will enter directly into 21-day combination cycles and will be given NOX66 therapy for 7 days and doxorubicin will be administered on Day 2 of each cycle. Treatment will be terminated upon disease progression, unacceptable toxicity, or a maximum of 6 cycles.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metastatic Soft-tissue Sarcoma
Keywords
Doxorubicin, Dose-escalation study, Dose-expansion study, Maximum tolerated dose
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Dose-Escalation Cohort 1: NOX66 800 mg + Doxorubicin
Arm Type
Experimental
Arm Title
Dose-Escalation Cohort 2: NOX66 1200 mg + Doxorubicin
Arm Type
Experimental
Arm Title
Dose-Escalation Cohort 3: NOX66 1800 mg + Doxorubicin
Arm Type
Experimental
Arm Title
Dose-Expansion Cohort: NOX66 + Doxorubicin
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
NOX66
Intervention Description
NOX66 800 mg (400 mg suppository twice daily [BID]).
Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles.
Intervention Type
Drug
Intervention Name(s)
NOX66
Intervention Description
NOX66 1200 mg daily (600 mg suppository BID).
Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles.
Intervention Type
Drug
Intervention Name(s)
NOX66
Intervention Description
NOX66 1800 mg daily (600 mg suppository thrice daily).
Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles.
Intervention Type
Drug
Intervention Name(s)
NOX66
Intervention Description
MTD of the combination of NOX66 and doxorubicin will be determined in the dose-escalation cohort of the study. The selected dose will be administered in combination with Doxorubicin.
Intervention Type
Drug
Intervention Name(s)
Doxorubicin
Intervention Description
Doxorubicin will be given at 75 mg/m^2 as an intravenous infusion on Day 2 of the 21-day cycle for up to 6 cycles.
Primary Outcome Measure Information:
Title
Dose Escalation: Number of patients with dose-limiting toxicities (DLTs)
Description
Determination of the MTD of NOX66 in combination with doxorubicin. MTD is defined as the dose level at which no more than 1 patient out of 6 experiences a DLT at the end of Cycle 1.
Time Frame
Cycle 1 of each dose (Cycle length is 21 days)
Title
Number of patients with adverse events (AEs) for NOX66
Description
Characterization of the safety and tolerability of NOX66.
Time Frame
Assessed up to 18 months from first combination treatment (Cycle1 Day 1)
Title
Number of patients with change in brain natriuretic peptide (BNP) levels from baseline
Description
The number of patients with BNP levels greater than 500 pg/mL and with BNP levels between 100 and 500 pg/mL from baseline will be presented.
Time Frame
Baseline (Day 1) and Cycles 1, 3, 5 and the end of Cycle 6 (Cycle length is 21 days) or Early termination (assessed up to 6 months)
Title
Number of patients with change in troponin levels from baseline
Description
Number of patients with change in troponin levels from baseline will be evaluated to characterize safety and tolerability of NOX66.
Time Frame
Baseline (Day 1) and Cycles 1, 3, 5 and the end of Cycle 6 (Cycle length is 21 days) or Early termination (assessed up to 6 months)
Secondary Outcome Measure Information:
Title
Dose-Escalation (Monotherapy): Maximum observed blood drug concentration (Cmax) for idronoxil and idronoxil metabolites
Description
Determination of single-and multiple-dose pharmacokinetics (PK) of idronoxil
Time Frame
Dose-Escalation (Monotherapy): Days 1 and 7
Title
Dose-Escalation (Monotherapy): Time to reach Cmax (Tmax) for idronoxil and idronoxil metabolites
Description
Determination of single-and multiple-dose PK of idronoxil
Time Frame
Dose-Escalation (Monotherapy): Days 1 and 7
Title
Dose-Escalation (Monotherapy): Area under the blood concentration time curve (AUC) from time 0 to the last measurable concentration (AUC-last) for idronoxil and idronoxil metabolites
Description
Determination of single-and multiple-dose PK of idronoxil
Time Frame
Dose-Escalation (Monotherapy): Days 1 and 7
Title
Dose-Escalation (Monotherapy): AUC from time 0 to end or dosing interval (τ) [AUCτ] for idronoxil and idronoxil metabolites
Description
Determination of single-and multiple-dose PK of idronoxil
Time Frame
Dose-Escalation (Monotherapy): Days 1 and 7
Title
Dose-Escalation (Monotherapy): AUC from time 0 to infinity (AUCinf) for idronoxil and idronoxil metabolites
Description
Determination of single-and multiple-dose PK of idronoxil
Time Frame
Dose-Escalation (Monotherapy): Days 1 and 7
Title
Dose-Escalation (Monotherapy): Terminal elimination rate constant (kel) for idronoxil and idronoxil metabolites
Description
Determination of single-and multiple-dose PK of idronoxil. Terminal elimination rate constant will be calculated from a semi-log plot of the blood concentration versus time (kel^a)
Time Frame
Dose-Escalation (Monotherapy): Days 1 and 7
Title
Dose-Escalation (Monotherapy): Terminal elimination phase half-life (T1/2)
Description
Determination of single-and multiple-dose PK of idronoxil
Time Frame
Dose-Escalation (Monotherapy): Days 1 and 7
Title
Dose-Escalation (Combination) and Dose-Expansion: Plasma concentrations of idronoxil and idronoxil metabolites or doxorubicin and doxorubicinol
Description
Determination of single-and multiple-dose PK of idronoxil and doxorubicin
Time Frame
Dose-Escalation (Combination): Days 2, 7, and 8; Dose-Expansion: Days 2 and 7
Title
Dose-Escalation and Dose-Expansion: Disease control rate (DCR)
Description
Evaluation of preliminary efficacy of NOX66 in combination with doxorubicin. DCR is defined as the percentage of patients with a best overall response of complete response (CR), partial response (PR) or stable disease, and will be assessed based on change from baseline imaging by (Response Evaluation Criteria in Solid Tumors [RECIST] v1.1.
Time Frame
At the end of Cycles 2, 4 and 6 (Cycle length is 21 days) and at Months 6, 9 and 12 and at the End of Study (assessed up to 18 months from first combination treatment)
Title
Dose-Escalation and Dose-Expansion: Objective response rate (ORR)
Description
Evaluation of preliminary efficacy of NOX66 in combination with doxorubicin. The ORR, defined as the percentage of patients with CR and PR, and will be assessed based on change from baseline imaging by (RECIST) v1.1.
Time Frame
At the end of Cycles 2, 4 and 6 (Cycle length is 21 days) and at Months 6, 9 and 12 and at the End of Study (assessed up to 18 months from first combination treatment)
Title
Dose-Escalation and Dose-Expansion: Complete response (CR)
Description
Evaluation of preliminary efficacy of NOX66 in combination with doxorubicin. CR will be assessed based on change from baseline imaging (RECIST) v1.1.
Time Frame
At the end of Cycles 2, 4 and 6 (Cycle length is 21 days) and at Months 6, 9 and 12 and at the End of Study (assessed up to 18 months from first combination treatment)
Title
Dose-Escalation and Dose-Expansion: Partial response (PR)
Description
Evaluation of preliminary efficacy of NOX66 in combination with doxorubicin. PR will be assessed based on change from baseline imaging (RECIST) v1.1.
Time Frame
At the end of Cycles 2, 4 and 6 (Cycle length is 21 days) and at Months 6, 9 and 12 and at the End of Study (assessed up to 18 months from first combination treatment)
Title
Dose-Escalation and Dose-Expansion: Stable disease (SD)
Description
Evaluation of preliminary efficacy of NOX66 in combination with doxorubicin. SD will be assessed based on change from baseline imaging (RECIST) v1.1.
Time Frame
At the end of Cycles 2, 4 and 6 (Cycle length is 21 days) and at Months 6, 9 and 12 and at the End of Study (assessed up to 18 months from first combination treatment)
Title
Dose-Escalation and Dose-Expansion: Progression free survival (PFS)
Description
Evaluation of preliminary efficacy of NOX66 in combination with doxorubicin. PFS is defined as the time in months from initial treatment until death, disease progression, or censoring.
Time Frame
Initial treatment until death, disease progression, or censoring (assessed up to 18 months from first combination treatment)
Title
Dose-Escalation and Dose-Expansion: Progressive disease (PD)
Description
Evaluation of preliminary efficacy of NOX66 in combination with doxorubicin. PD will be assessed based on change from baseline imaging (RECIST) v1.1.
Time Frame
At the end of Cycles 2, 4 and 6 (Cycle length is 21 days) and at Months 6, 9 and 12 and at the End of Study (assessed up to 18 months from first combination treatment)
Title
Dose-Escalation and Dose-Expansion: Overall survival (OS)
Description
Evaluation of preliminary efficacy of NOX66 in combination with doxorubicin. OS is defined as the time in months from initial treatment until death or censoring.
Time Frame
Initial treatment until death, or censoring and at the End of Study (assessed up to 18 months from first combination treatment)
Title
Dose-Escalation and Dose-Expansion: Change from baseline in European Organization for Research and Treatment Core Quality of Life Questionnaire v3.0) (EORTC QLQ-C30)
Description
Determination of quality of life (QOL) of NOX66 in combination with doxorubicin. The questionnaire assesses important functioning domains (e.g., physical, emotional, social) and common cancer symptoms (e.g., fatigue, pain, nausea, vomiting, appetite loss). The instrument is composed of 30 items. All symptom scales range from 1-4 with higher values representing higher levels of symptoms, except for the items that evaluate the overall quality of life which are rated on a 7-point scale (range 1-7) where higher scores represent a better quality of life.
Time Frame
Cycle 1 Day 1 (Cycle length is 21 days) until Months 6, 9 and 12 of the follow-up period and at the End of Study (assessed up to 18 months from first combination treatment)
Title
Fatigue change from baseline measured using the EORTC QLQ-FA12 questionnaire
Description
Determination of quality of life (QOL) of NOX66 in combination with doxorubicin. Fatigue will be measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - EORTC QLQ-FA12. The QLQ-FA12 incorporates three multi-item scales to assess physical fatigue, emotional fatigue, and cognitive fatigue. In addition, two single items assess interference with daily life and social sequelae. All of the scales and single-item measures range in score from 0 to 100. For all the scales and single items, a high score represents a high level of symptomatology or problems.
Time Frame
Cycle 1 Day 1 (Cycle length is 21 days) until Months 6, 9 and 12 of the follow-up period and at the End of Study (assessed up to 18 months from first combination treatment)
Title
Change from baseline in brief pain inventory- Short Form (BPI-SF) questionnaire
Description
Determination of quality of life (QOL) of NOX66 in combination with doxorubicin. The effects of NOX66 on pain and other cancer-related signs and symptoms will be explored. Worst pain, general pain and pain's interference with daily life will be assessed during the study drug using the BPI-SF. The BPI-SF comprises a total of 15 items measuring 2 domains: pain severity and pain interference. Items measuring pain severity (including 'worst pain') are rated on an 11 point numeric rating scale ranging from 0=No pain to 10=Pain as bad as you can imagine. Higher scores mean a worse outcome.
Time Frame
Cycle 1 Day 1 (Cycle length is 21 days) until Months 6, 9 and 12 of the follow-up period and at the End of Study (assessed up to 18 months from first combination treatment)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult patients with a histologically confirmed diagnosis of metastatic or recurrent soft tissue sarcoma
Patients for whom treatment with doxorubicin is considered to be appropriate
Left ventricular ejection fraction ≥ 50%
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Disease that is considered measurable according to RECIST v1.1.
Exclusion Criteria:
Histologically or cytologically confirmed Kaposi's sarcoma, gastrointestinal stromal tumor (GIST), extra-skeletal myxoid chondrosarcoma, epithelioid hemangioendothelioma, and desmoid tumor
Untreated metastases to the central nervous system
Received previous treatment with anthracyclines and anthracenediones
Previous radiation therapy to the mediastinal or pericardial area
A known allergy to any of the treatment components
Patient not willing to use suppositories
Patients with a colostomy
Patients who have had a colectomy (total or left hemicolectomy) with re-anastomosis
Patients for whom administration of the suppositories are likely to cause pain (e.g., inflamed hemorrhoids, fissures, or lesions of the anus or rectum)
Patients with fecal impaction, chronic idiopathic constipation, or chronic diarrhea or alternating irritable bowel disease
Patients with inflammatory bowel disease
Previous treatment with an investigational agent or the non-approved use of a drug or device within 4 weeks before study entry
Uncontrolled diabetes mellitus
Patients who require concomitant use of strong inhibitors or inducers of CYP3A4, CYP2D6 or P- glycoprotein (P- gp)
Facility Information:
Facility Name
City of Hope
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Facility Name
Mayo Clinic Florida - Oncology
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224
Country
United States
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
Site name Washington University School of Medicine in Saint Louis
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma
We'll reach out to this number within 24 hrs